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Abstract: In the natural world, there are many creatures with venoms that have interesting 
and varied activities. Although the sea anemone, a member of the phylum Coelenterata, 
has venom that it uses to capture and immobilise small fishes and shrimp and for protection 
from predators, most sea anemones are harmless to man. However, a few species are 
highly toxic; some have venoms containing neurotoxins, recently suggested as potential 
immune-modulators for therapeutic application in immune diseases. Phyllodiscus semoni is 
a highly toxic sea anemone; the venom has multiple effects, including lethality, hemolysis 
and renal injuries. We previously reported that venom extracted from Phyllodiscus semoni 
induced acute glomerular endothelial injuries in rats resembling hemolytic uremic 
syndrome (HUS), accompanied with complement dysregulation in glomeruli and suggested 
that the model might be useful for analyses of pathology and development of therapeutic 
approaches in HUS. In this mini-review, we describe in detail the venom-induced acute 
renal injuries in rat and summarize how the venom of Phyllodiscus semoni could have 
potential as a tool for analyses of complement activation and therapeutic interventions in HUS. 
Keywords: sea anemone; hemolytic uremic syndrome; complement; complement 
regulators; marine envenomation; renal failure 
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1. Introduction 
Diverse types of land animals produce natural toxins that are harmful to humans; these include 
venoms from snakes [1–3], spiders [4–6], scorpions [7], caterpillars [8] and platypus [9]. In 
marine/aquatic environments [10], various situations in which envenomation by aquatic animals has 
injured people have been reported. Culprits include cnidarians such as fire coral (Millepora  
alcicornis) [11,12]. Portuguese man-of-war and other jellyfishes such as box jellyfishes (Chironex 
fleckeri) [13], sea wasp (Chiropsalmus quadrigatus, called Habu-kurage in Japan) [14] and irukandiji 
(Carukia barnesi) [15,16], sea anemones [15,17,18], seaworms, echinoderms, molluscs such as the 
cone shell and the blue-ringed octopus, fishes such as scorpion fishes and sea snakes, all of which have 
toxic bites or stings for feedings and protection from enemies (Table 1). Other marine organisms cause 
food poisoning, such as ciguatera poisoning caused by consuming the flesh of Lutjanids, Serranids, 
Epinephelids, Lethrinids and so on [15], shellfish poisoning cause by Brevetoxins and domoic acid [19], 
and neurotoxin (Tetrodotoxin) poisoning of puffer fishes or globefishes [19]. Components of some 
venoms are highly toxic for humans and can rarely cause multiple organ failure and lethal shock. 
Table 1. Marine envenomations that cause severe injuries in humans. 
Classification Type of 
envenomation 
References 
Phylum Genus, Species 
Cnidaria    
 Jellyfishes   
 Portuguese man-of-war (Physalia physalis) sting [15] 
 Irukandji jellyfish (Carukia barnesi, Malo kingi) sting [15,16] 
 Mauve stinger (Pelagia noctiluca) sting [15] 
 Box jellyfish (Chironex fleckeri) sting [13] 
 Chesapeake Bay sea nettle (Chrysaora quinquecirrha) sting [15] 
 Sea wasp (Chiropsalmus quadrigatus) sting [14] 
 Fire coral (Millepora alcicornis) sting [11,12] 
 Sea anemones   
 The Hell’s Fire sea anemone (Actinodendron plumosum) sting [10,20] 
 Night sea anemone (Phyllodiscus semoni) sting [18,21] 
 Haddon’s carpet anemone (Stichodactyla haddoni) sting [22] 
 Snakelock’s anemone (Anemonia sulcata (=Anemonia viridis)) sting [23] 
 Condylactis sp. sting [24] 
Echinodermata    
 Sea urchins   
 Flower sea urchin (Toxopneustes pileolus) sting [25] 
 Purple sea urchin (Paracentrotus lividus) sting [26] 
 Sea star   
 Crown-of-Thorns starfish (Acanthaster planci (Linnaeus)) sting [27,28] 
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Table 1. Cont.  
Mollusca    
 Cone shells (Conidae) sting [29,30] 
 Blue-ringed octopus (Hapalochlaena) bite [31,32] 
 Shellfish poisoning by brevetoxins and domoic acid food [19] 
Chordata    
 Stone fish, lion fish, scorpionfish (Scorpaernidae) sting [20,33–35] 
 Stingray (Dasyatidae) sting [36] 
 Weeverfish (Trachinus) sting [37] 
 Striped eel catfish (Plotosus lineatus, Plotosus japonicus) sting [38] 
 Globe fishes (Tetraodontidae) food [19] 
Hydrophiidae    
 Hydorophis, Laticauda, Pelamis bite [39,40] 
On the other hand, some toxins have found use as experimental agents and some have been 
investigated as therapeutics. For example, it was reported that NN-32 purified from the venom of the 
cobra Naja naja might have anti-cancer effects in animal models [41]. A number of venoms have been 
shown to have complement (C) activating components that directly or indirectly contribute to tissue 
damage [3,5,7,42]. One of these, the C3-like protein cobra venom factor (CVF) purified from venom 
of the Egyptian or Thai cobra, is widely used as an experimental tool to induce excessive activation 
and consumption of C in animal models [43–47]. A humanized CVF has been tested as a therapeutic 
approach in man [48,49]. The C activating component of brown recluse spider (Loxosceles genus) 
venom has also been proposed as a tool for biological purposes [50]. 
Research on the venoms of marine animals has also yielded interesting and clinically relevant data. 
For example, dideoxpetrasynol A, a protein toxin from the sponge Petrosia sp., caused apoptosis in 
human melanoma cells [51], Chiropsalmus quadrigatus toxins (CqTX) induced apoptosis in glioma 
cell lines [52], extracts from Acanthaster planci (Crown-of-Thorns) starfish also induced apoptosis in 
human breast cancer cell lines [53]. The pore-forming proteins Bc2 and equinatoxin (EqTx-II) from 
sea anemones were cytotoxic for glioblastoma cell lines [54], and another pore-forming toxin, 
membrane-attack complex/perforin (MACPF) domain lethal toxin from the nematocyst venom of the 
Okinawan sea anemone Actineria villosa [55] has been proposed as a cytotoxic agent to target some 
cancers. Several other toxin-derived agents have been shown to have antitumor activities and proposed 
as therapeutics [56–59]. As examples of toxins with other targets, the toxin APETx2 of the sea 
anemone Anthropleura elegantissima has been used as a pharmacological tool to inhibit Nav1.8 in rat 
dorsal root ganglion neurons [60] in order to prevent and treat inflammatory and postoperative  
pain [61–63], a sea anemone polypeptide, ATX II, has been used in the long QT syndrome model [64] 
and was shown to have an antiarrthythmic action [65], and the ShK toxin from the sea anemone 
Stichodactyla helianthus is a potent blocker of the Kv1.3 potassium channel, inhibits T lymphocyte 
proliferation [66] and has been proposed as a therapeutics for autoimmune diseases such as multiple 
sclerosis [67]. Of note, ziconide is a derivative of conotoxin derive from a coneshell, Conus magus, 
and successfully used as a non-opioid intrathecal therapy [68,69]. Therefore, research on new  
toxins from marine animals might have potential to develop therapeutic agents (Table 2) and  
experimental materials. 
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Table 2. Agents extracted from venom of marine organisms and derivatives. 
Organisms Agents Targets References
(A) Extracted agents 
Jellyfish    
Chiropsalmus quadrigatus CqTX glioma cells [52] 
Chrysaora quinquecirrha Sea nettle nematocyst venom (SNV) cancer cells [70] 
Starfish    
Crown-of-Thorns starfish extracts breast cancer cells [53] 
Sponge    
Callyspongia truncate callystatin A cancer cells [71] 
Discodermia dissoluta (+)-Discodermolide cancer cells [57] 
Dysidea arenaria arenastatin A cancer cells [71] 
Hyrtios altum altohyrtin A cancer cells [71] 
Petrosia sp. dideoxpetrasynol A melanoma cells [51] 
Spirastrella spinispirulifera, 
Hyrtios erecta 
Spongistatin 1 cancer cells, leukemia [72] 
Sea anemone    
Actineria villosa MACPF cancer cells [55] 
Actinia equina EqTX-II glioblastoma cells [54] 
Anemonia viridis ATX-II antiarrthymia [65] 
Anthropleura elegantissima APETx2 inflammation, postoperative pain [60–63] 
Bunodosoma caissarum Bc2 glioblastoma cells [54] 
Radianthus macrodactylus PTX-A cancer cells [59] 
Stichodactyla helianthus sticholysin I (StI) cancer cells [56] 
Stichodactyla helianthus ShK T lymphocyte proliferation, 
Autoimmune diseases 
[66,67] 
(B) Derivatives of extracted agents 
Sponge    
Discodermia dissolute (+)-Discodermolide-paclitaxel hybrids cancer cells [73] 
Dysidea arenaria analogoue of arenastatin A cancer cells [58] 
Sea anemone    
Stichodactyla helianthus StI W111C cancer cells [74] 
Stichodactyla helianthus ShK analogues autoimmune diseases [75] 
Cone shell    
Conus magus Ziconotide (a derivative of conotoxin) non-opioid intrathecal therapy [68,69] 
This minireview focuses on the sea anemone, a coelenterate of the phylum Cnidaria. Sea anemones 
have sting venoms to catch and immobilize small fishes and shrimps for feeding and protection. Most 
are not harmful for humans or only cause mild dermatitis. A few species possess highly toxic venoms 
and are hazardous for humans. The Hell’s Fire sea anemone (Actinodendron plumosum) is named for 
the severe skin ulceration caused by its sting [10,20]. Envenomation by the sea anemone Stichodactyla 
haddoni caused shock and organ failure, including fulminant hepatitis [22,24]. Phyllodiscus semoni  
(P. semoni) is another sea anemone dangerous to humans. The sting usually induces severe dermatitis 
with ulceration and profound swelling in the regions of contact [18,21]. More serious sequelae of 
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envenomation by P. semoni include the development of acute renal failure without evidence of 
dysfunction of other organs [18]. 
We recently reported that the venom, termed PsTX-T, extracted from nematocysts of P. semoni had 
nephrotoxin activity and induced acute renal injuries in rodents [76]. This nephrotoxin acutely induced 
glomerular endothelial injuries, with a similar pathology to atypical hemolytic uremic syndrome (aHUS). 
This animal model might be attractive to analyze pathological mechanisms and to develop new agents 
for therapeutic use in aHUS. In the present mini review, we summarize the nature and time-course of 
the natural venom-induced acute renal injuries and explore the mechanisms of nephrotoxicity of  
P. semoni venom nephrotoxin in a rodent system. 
2. Acute Kidney Injuries Induced by Natural Venoms 
Natural venoms represent a rare cause of acute kidney injuries. These can be broadly divided into 
three categories; food poisons, biting poisons and sting poisons (envenomation), as indicated in Table 3. 
Renal injury has been reported following envenomation by snakes, spiders, caterpillars and  
scorpions [1,2,4,8,77–79]. Acute kidney injuries (AKI) induced by natural venoms included acute 
tubular necrosis caused by impairment of renal hemodynamics, intravascular hemolysis, 
rhabdomyolysis, disseminated intravascular coagulation (DIC) and direct toxin-mediated effects, 
including thrombotic microangiopathy similar to that observed in HUS. There are many reports of 
renal injuries caused by snake bites [78,80], usually accompanied by systemic organ failures and/or 
shock. For instance, snake envenomation often induced hemolysis, rhabdomyolysis and DIC, and 
sometimes was accompanied by acute renal failure with thrombotic microangiopathy, particularly 
following bites of taipan (Oxyuranus scutellatus) [81], tiger snake (Notechis scutatus) [82], or the 
“Fer-de-Lance” pit viper (Botherops lanceolatus) [83]. In Japan, envenomation by habu-snakes 
induced systemic reactions with hemolysis, DIC and AKI [84]. The habu-snake venom was also 
reported to directly induce acute endothelial injuries in glomeruli [85]. In addition to snake bites, stings 
of bees and wasps, envenomation by scorpions and spiders and other causative creatures have been 
reported as causes of AKI (Table 3). 
Renal injuries caused by marine animal toxins can also divided into these three categories. Marine 
envenomation can cause dermal injuries, neurotoxicity, hemolysis, and systemic shock reactions, 
including anaphylactic shock; some victims developed acute renal failure (Table 3). The causes of 
renal injuries include systemic shock, hemolysis, rhabdomyolysis, and direct nephrotoxic effects. For 
instance, acute renal failure with hemolysis was caused by a Portuguese man-of-war sting [86,87]; 
minimal change nephritis was described in association with fire coral (Millepora species) exposure [12]; 
tetrodotoxin of puffer fish is orally active and induces AKI as well as other organ failures [88]; 
envenomation by sea anemone and sea snakes was also reported to cause acute renal 
failure [18,39,89,90]. 
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Table 3. Natural toxins that induce acute kidney injuries in humans and animal 
experimental models. 
 Organisms 
Type of renal 
injuries/pathology 
Human or 
animal models 
(References) 
1. Land envenomation 
(1) Biting     
 Snakes: viper (Viperidea) 
and cobra (Elapidae) 
   
  Habu snakes 
(Trimeresurus) 
Mesangial proliferative 
glomerulonephritis, mesangial 
injuries 
[84,85,91,92] 
  Mamushi snake 
(Gloydius blomhoffii) 
ATN * with hemolysis [92] 
  Tiger snake  
(Notechis scutatus) 
TMA **, ATN with 
rhabdomyolysis 
[82,93] 
  “Fer-de-Lance” pit viper 
(Botherops lanceolatus) 
TMA [83] 
  Bothrops (B.) jararaca, 
B. jarararacussu, 
B.moojeni 
Renal cortical necrosis [1,94,95] 
  Brazilian rattlesnake 
(Crotalus durissus) 
Rhabdomyolysis and hemolysis 
related renal injuries 
[96–98] 
  Russell’s viper  
(Vipera russellii) 
Cortical necrosis, ATN with 
rhabdomyolysis, mesangiolysis 
[2,99] 
  Lansberg’s pit viper 
(Porthidium lansbergii) 
ATN, glomerular and tubular 
changes 
[100,101] 
  Taipan  
(Oxyuranus scutellatus) 
HUS *** [81] 
 Spider    
  Brown recluse spider 
(Loxosceles intermedia) 
Hemolysis and rhabdomyolysis 
related renal injuries, 
glomerulonephritis 
[4,102] 
(2) Sting     
 Honey Bee  
(Apis mellifera) 
 ATN with hemolysis and 
rhabdomyolysis, renal ischemia 
[103] 
 Hornet  
(Vespa crabro) 
 ATN with hemolysis and 
rhabdomyolysis 
[104] 
 Wasp  
(Vespa magnifica) 
 ATN with hemolysis and 
rhabdomyolysis, or by direct 
toxic effects  
[105,106] 
 Iranian scorpion 
(Hemiscorpius lepturus) 
 HUS [107,108] 
 Lonomia caterpillars 
(Lonomia obliqua) 
 Hemodynamic changes and 
disseminated intravascular 
coagulation related renal injuries 
[8,109] 
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Table 3. Cont.  
(3) Food poison     
 Mushroom    
  Cortinarius sp. Chronic interstitial nephritis [110,111] 
  Amanita (A.) phylloides, 
A. proxima,  
A. smithiana,  
A. pseudoporphyria,  
A. boudierim,  
A. gracilior,  
A. echinocephala 
ATN, acute interstitial 
nephritis 
[112–116] 
  Lepiota sp. Acute renal failure  
(no detail pathology) 
[117] 
 Squirting cucumber 
(Ecbalium Elaterium) 
 Renal failure  
(no detail pathology) 
[118] 
 Herb    
 Chinese herb  
(Aristolochia sp.) 
 Chinese harb nephropathy, 
ATN, tubulointerstitial 
nephritis 
[119,120] 
2. Marine envenomation
(1) Biting     
 Sea snakes  
(Hydrophis cyanocinctus, 
Laticauda semifasciata) 
 ATN, renal ischemia [39,89,90,121]
(2) Sting     
 Lionfish (genus Pterois)  ATN [122] 
 Jelly fishes    
  Portuguese man-of-war 
(Physalia physalis) 
ATN with hemolysis [86,123] 
  Box-jellyfish 
(Chirodropids) 
ATN [124] 
 Fire coral  
(Millepora species) 
 Minimal change nephrotic 
syndrome 
[12] 
 Sea anemone  
(Phyllodiscus semoni, 
Condylactis sp.) 
 ATN, TMA, renal ischemia [18,24,76] 
(3) Food poisons     
 Puffer (Globe) fish 
(Lagocephalus, Lactoria) 
 ATN with rhabdomyolysis, 
renal ischemia 
[88,125,126] 
* Acute tubular necrosis; ** Thrombotic microangiopathy; *** Hemolytic uremic syndrome. 
3. Envenomation by Sea Anemones including P. semoni and the Acute Kidney Injuries 
The sea anemone, categorized in phylum coelenterate (Cnidaria), class Anthozoa, is armed with 
venom-secreting nematocysts to aid in the capture of prey and to protect from predators. Most sea 
anemones are harmless for man or at worst cause dermatitis by contact irritants/toxins. However, 
venom of some sea anemones is extremely harmful for man; Actinodendron plumosum (Hell’s Fire sea 
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anemone), Actineria villosa (Okinawan sea anemone, called fusa-unbachi in Japan) and P. semoni all 
cause severe injury including dermatitis [15,127], hepatitis [24], renal failure [18] and anaphylactic 
shock [22]. The sea anemones Anemonia sulcata and Anemonia equine, were reported to cause severe 
dermatitis with hyper- and parakeratosis with many infiltrative cells in the skin [128], while toxins 
from other sea anemones, including Actinia equina, Anemonia sulcata, Anthopleura xanthgrammica, 
Bunodosoma granulifera, Bunodosoma caissarum and Stichodactyla helianthus, were cytolytic, 
haemolytic, neurotoxic and cardiotoxic [129–135]. 
P. semoni is categorized in Aliciidae, a family of sea anemones, commonly called “night sea 
anemone”, distributed in the Western Pacific ocean; it is also called in Japanese “unbachi-isoginchaku” 
which means “sea-wasp anemone” in Okinawa (South Japan). The shape of the animal changes with 
its circumstances (Figure 1A). The sting induces severe dermatitis with local ulceration and swelling 
that often takes months to resolve. We recently reported a more serious sequela of envenomation by 
P. semoni; the victim developed unexplained acute renal failure without evidence of dysfunction of 
other organs [18,76]. The venom, PsTX-T, which was extracted from the nematocysts and a 115 kDa 
protein extracted from venom which we called PsTX-115, also induced nephrotoxic effects in 
rodents [76]. From the venom, haemolytic protein toxins were also identified, a 20 kDa protein,  
PsTX-20A, and 60 kDa proteins, PsTX-60A and -60B [136,137]. 
Figure 1. Photographs of Phyllodiscus semoni (Unbachi-isogintyaku) and nematocysts. 
(A) The intact organism as found in the seas off Okinawa Island; (B) Close-up view of the 
globular vesicles (white arrows) with nematocysts. Scales bar is in the upper right corner of 
frame B. The underwater photos were taken by M. Mizuno. 
 
4. Thrombotic Microangiopathy, Renal Pathology and Renal Function after Exposure of Rats to 
Venom of P. semoni, PsTX-T  
We reported that acute renal injuries were induced by intravenous injection of 0.03 mg/body of 
crude venom of P. semoni, PsTX-T, in rats [76]. Although the nephrotoxin was purified as the ~115 kDa 
protein extracted from venom (PsTX-115), PsTX-T was more convenient to obtain the enough amount 
and was useful to investigate the pathology and the further experiments. Therefore, we used PsTX-T to 
investigate the detail pathology. The venom had specific acute nephrotoxic effects because the toxin 
directly bound in glomeruli. Renal damage included endothelial injuries in glomeruli and, later, 
extended into glomerular epithelial cells. Electron microscopy showed endothelial injuries as early as 
~5 mm ~5 cm 
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10 min after PsTX-T administration; after 24 h, the renal pathology was mainly thrombotic 
microangiopathy with subendothelial widening of the glomerular capillary, mesangiolysis and 
deposition of fibrin-like material (Figure 2A-1 to -5). Up to day 5, fibrin exudation from glomerular 
capillaries was observed, accompanied with severe tubular necrosis (Figure 2). Crescent formation was 
observed in focal and segmental glomeruli in some rats on day 10 after injection of PsTX-T  
(Figure 2D-1 to -5). After 14 days, focal glomerular sclerosis remained in renal cortex, but most 
glomeruli were restored (Figure 2E-1 and -2). At that time, most of the renal tubular necrosis was also 
recovered (Figure 2E-3 to -5). Semi-quantitative microscopy findings are summarised in Figure 3A. 
When we analyzed accumulation of total inflammatory cells in glomeruli, the number of inflammatory 
cells peaked between day 3 and day 5 (Figure 3D). The glomerular neutrophil infiltration, likely a 
major feature of the pathology, peaked between 24 h and day 3.  
Figure 2. Time course of renal pathology after injection of PsTX-T. A-1, B-1, C-1, D-1,  
E-1 and F-1 are glomeruli in cortex under 200× magnifications. A-2, B-2, C-2, D-2, E-2 
and F-2 are glomeruli under 400× magnifications. A-3, B-3, C-3, D-3, E-3 and F-3 are 
tubuli in cortex under 200× magnifications. A-4, B-4, C-4, D-4, E-4 and F-4 are outer 
medulla under 200× magnifications. A-5, B-5, C-5, D-5, E-5 and F-5 are inner medulla 
under 200× magnifications. For light microscopic (LM) analyses, tissues were fixed in 
methacarn overnight and embedded in paraffin. Two-micrometer sections were stained 
with periodic acid-Schiff. Time course is noted across the top of the plates. Arrows indicate 
deposition of fibrin-like materials. Arrowheads indicate cellular proliferation. Scale bars 
are in the upper left corner of frames A-1 to A-5. Adapted from [76], Copyright © 2007, 
with permission from Elsevier. 
 
100 μm 
50 μm 
100 μm 
100 μm 
100 μm 
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Figure 3. Summary of time course of renal injuries, C3b/C5b-9 deposition and infiltration 
of inflammatory cells in glomeruli after intravenous injection of PsTX-T. Panel A 
summarises severity of renal injuries assessed under light microscopy and scored as -, no 
change, through +++ injury, scaled according to the number of affected glomeruli and area 
of tubular injuries: -, no change; +/-, minimal change; +, less than 25%; ++, between 25% 
and 75%; +++, widespread injury with severe damage involving over 75%. Panels B and C 
summarise degrees of C3 deposition and membrane attack complex (MAC; C5b-9) 
deposition in glomeruli of the kidney after PsTX-T administration; the degree of deposition 
of C3b or C5b-9 was scored as −, negative, through +++ according to the positive staining 
area: −, negative staining; +/−, minimal staining; +, positive staining less than 25%;  
++, between 25% and 50%; +++, more than 50%. Panel D shows total number of infiltrating 
inflammatory cell recognized as leukocyte common antigen (LCA)-positive cells and RP-3 
positive neutrophils in glomeruli. Panel E shows time course of impaired renal function. 
Cre: creatinine, BUN: blood urea nitrogen. Each value is shown as mean ± SE. 
 
The time course of renal dysfunction is summarized in Figure 3E. Briefly, serum creatinine and 
blood UN levels were elevated at 6 h after administration of PsTX-T although ultra-microscopic 
changes had already been observed at 10 min after i.v. injection of PsTX-T. Levels of serum creatinine 
and blood UN peaked between day 3 and 5 after PsTX-T injection (Table 4). Decreases of blood 
hemoglobin and hematocrit levels were observed on day 7. 
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Table 4. Causes of renal thrombotic microangiopathy including thrombotic 
thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS). 
1. Infection-related 
 Bacteria  
  Escherichia coli (O157:H7, O104:H4, etc.), Shigella dysenteriae type 1, 
Salmonella typhi, Salmonella pneumonia, Campylobacter jejuni,  
Yersinia pseudotuberculosis, Pseudomonas sp., Bacteroides sp., 
Mycobacterium tuberculosis 
 Virus  
  Rubella, Coxsackievirus, Echoviruses, Influenza virus, Epstein-Barr virus, 
Rotaviruses, Cytomegalovirus, Human immunodeficiency virus 
2. Drug-related 
 Immunosuppressant and 
chemotherapy 
 
  Cyclosporine, Tacrolimus, OKT3, Dopidogrel, Valacyclovir, Cyclosporine, 
Mitomycin C, Cisplatin, Daunorubicin, Cytosine arabinoside, Methyl 
CCNU, Chlorozotocin, Zinostatin, Deoxycoformycin, Gemcitabine 
 Other drugs  
  Oral contraceptives, Quinine, Penicillin, Penicillamine, Metronidazole, 
Ticlopidine, Clopidogrel 
3. Toxins 
  Carbon monoxide, Bee sting, Arsenic poisoning, Snake bites, Iodine, etc. 
4. ADAMTS 13 * related TTP 
  Deficiency of ADAMTS 13 activity, Inhibitor of ADAMS 13 (antibody to 
ADAMS 13) 
5. Abnormalities of complement components and complement regulators (aHUS) 
  Mutations in complement regulators/components (factor H, factor I, 
factor B, C3, CD46) 
  Anti-factor H autoantibodies, etc. 
6. Secondary 
 Malignant neoplasm  
 Transplantation (conditioning for hematopoietic stem cell transplantation, GVHD **, 
chronic transplant rejection) 
 Autoimmune disease  
  Systemic lupus erythematosus, Scleroderma renal crisis, Antiphospholipid 
antibody syndrome, Polyarteritis nodosa, Primary glomerulopathies 
(MPGN ***, etc.), malignant nephrosclerosis with malignant hypertension 
7. Other reasons 
 Pregnancy or postpartum  
 Radiation  
This table is modified from the following references [138–142]. * A disintegrin and metalloproteinase with a 
thrombospondin type 1 motif, member 13; ** Graft versus host diseases; *** Membranoproliferative glomerulonephritis. 
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5. Impairment of Complement Regulator Expression and Enhanced Complement Deposition in 
Kidney after Exposure of PsTX-T in Rat  
Deposition of complement activation products C3b and C5b-9 was observed as early as 1 h after 
injection of PsTX-T and peaked at 24 h (Figure 3B,C). Complement deposition appeared to precede 
morphological changes as assessed by IF analysis. Decreased expression of the complement regulators 
(CRegs) CD55 (decay accelerating factor; DAF) and CD59 accompanied the severe morphologic 
changes of renal injury [76]. As disease resolved at later timepoints, glomerular CRegs expression 
such as CD55 was restored in parallel with recovery of renal integrity (Figure 4).  
Figure 4. Distribution of CD55 in glomeruli after PsTX-T injection. After administration 
of PsTX-T, binding of anti-CD55 was decreased at 6 h (B) and lowest between 24 h and 
3 days (C and D). Expression of CD55 was restored in most of the glomeruli by 14 days 
after injection of PsTX-T (G). For immunohistological analysis, kidney was embedded in 
OCT compound (Sakura Finetechnical Co., Tokyo, Japan), snapfrozen in liquid nitrogen, 
cryostat-sectioned at 2 μm, and fixed with acetone for 10 min at room temperature. To 
investigate the expression of CD55, sections were incubated with anti-rat CD55 (clone; 
RD-III7) followed by fluorescenin isothiocyanate-labeled anti-rat CD55 as our previous 
report [76]. Original magnifications are shown in right bottom of each frame. Scale bars 
are in the upper right corner of frames A and F. 
 
6. Thrombotic Microangiopathy in Kidney, HUS, aHUS and Impairment of  
Complement Regulation 
Thrombotic microangiopathy is induced under various situations (Table 4). Typical HUS is a 
thrombotic microangiopathy with hemolytic anemia, thrombocytopenia and acute renal failure that is 
epidemic, diarrhea related and caused by Verotoxin (Shiga toxin)-producing Escherichia coli 
(O157:H7, O104:H4). Atypical HUS (aHUS) is non-diarrhea related and familial. At least half of 
aHUS cases are caused by impairment of C regulation. Mutations in factor H, CD46 (membrane 
50μm 
100μm 
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cofactor protein; MCP), factor I factor B, and C3, or autoantibodies against factor H have all been 
described as causes of aHUS [138,143,144]. 
Plasma exchange therapy and plasma infusion were the conventional management for aHUS [145]. 
Renal replacement therapy was performed in patients with renal failure. A complement-targeted 
therapy, eculizmab which is an anti-C5 antibody developed to prevent C-activation related anemia in 
patients with PNH and improve survival [146], has recently been used to treat aHUS associated with C 
dysregulation [147]. Although recurrence of aHUS and graft loss is common post-renal  
transplantation [148,149], long-term remission and graft survival was reported in post-transplant aHUS 
patients treated with eculizmab [150,151]. Eculizmab has thus become attractive as a therapeutic 
choice for aHUS associated with C dysfunction. For aHUS, and perhaps also for typical HUS, there is 
potential to develop new and presumably more effective anti-complement therapies; development of 
better animal models of aHUS with thrombotic microangiopathy for testing new agents. 
The PsTX-T-induced renal injuries observed in the rat model were accompanied by impaired local 
C regulation and C activation, and the pathology closely resembled that seen in the acute phase of 
HUS, later progressing to focal and segmental glomerular sclerosis. In this model, we also showed that 
an anti-complement agent, sCR1, improved the renal injuries [76]. Until now, many anti-C agents have 
been developed to try to control pathologic conditions and were reported to be useful in various animal 
modes [152–154]. In the present, replacement therapy of C1-inhibitor is also another established 
treatment for hereditary angioedema in addition to anti-C5 antibodies for C-dependent hemolytic 
anemia in patients with paroxysmal nocturnal hemoglobinuria, respectively [155,156]. Like these, 
development of anti-C agents is an important category and development of new animal models may 
have large potential to test the newly developed agents. These findings suggest that PsTX-T induced 
renal injury provides an animal model that will be useful in testing anti-C therapies for aHUS and 
typical HUS.  
7. Conclusion and Future 
The nematocyst-extracted venom, PsTX-T, acutely caused thrombotic microangiopathy with 
C activation and decreased membrane CReg expression in rat glomeruli, confirming that PsTX-T was 
a direct nephrotoxin. The nature and time course of glomerular injuries after administration of PsTX-T 
closely resembled the course and pathology seen in HUS, including local C activation and loss of 
C regulators in the kidney. Suppression of C activation until expression of CReg recovers inhibits the 
renal injuries induced by PsTX-T. This model might be useful to search for pathologic mechanisms 
and to develop therapeutic approach for HUS, especially to develop anti-complement therapy. 
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